Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind

Eli Lilly was upgraded to Buy following a 13% pullback, with strong Q4 guidance and potential for 25% topline growth in 2026. The Kelonia and Orna Therapeutics acquisitions strengthen its position in in vivo CAR-T therapies, supporting longer-term growth. Offsetting this, the weight loss franchise now represents 56% of revenue and faces pricing, legal, and regulatory risks, making volume-versus-price trends a key monitor.

Analysis

The setup is less about a clean re-rating and more about whether the market is underestimating how much of Lilly’s future mix can be pushed into higher-durability, higher-multiple biology. In vivo CAR-T is strategically important because it potentially shifts cell therapy from a one-time, service-heavy model into a scalable drug franchise; if Lilly can execute, that expands not just addressable markets but also gross margin stability relative to ex vivo peers. The M&A angle matters because it buys time-to-market and optionality, which in this space is often more valuable than pure pipeline breadth.

The bigger second-order issue is that the obesity franchise is already so large that it is becoming the valuation anchor, not just a growth driver. Once a single category is >50% of revenue, any incremental slowdown in net price realization or payer pushback can compress the entire multiple even if unit volume keeps rising. The market may be underappreciating how quickly the mix can shift from “scarcity premium” to “managed-care commodity” if competitors force rebates or if utilization normalizes after an initial surge.

Catalyst timing is uneven. Over the next few weeks, guidance and sell-side upgrades can extend the bounce; over the next 3-6 months, the key is whether prescription volume inflects faster than gross-to-net deterioration. Over 12-24 months, the real upside comes from proving that the obesity franchise can coexist with a second growth engine in immunology/oncology, which would justify a structurally higher multiple than a single-product story.

The consensus may be too focused on near-term top-line growth and not enough on the durability of that growth. If pricing pressure shows up before in vivo CAR-T contributes meaningfully, the stock could trade like a premium pharma with a vulnerable crown jewel rather than a platform compounder. Conversely, if volume acceleration offsets price erosion and the M&A assets show credible human data, the current pullback likely marks an entry point rather than a warning signal.

Key Decisions for Investors

• Go long LLY on a 3-6 month horizon, but size it as a quality-growth rebound rather than a low-vol value trade; target 10-15% upside if volume stays ahead of net pricing compression.
• Buy a call spread in LLY (3-6 months out) to express upside from guidance and pipeline optionality while capping premium if obesity pricing decelerates faster than expected.
• Pair trade: long LLY / short a basket of obesity-exposed peers with weaker pipeline depth over 6-12 months; the trade works if the market rewards durability and penalizes single-franchise risk.
• Use weakness to add only if prescription volume data remains ahead of gross-to-net deterioration; if weekly/quarterly utilization flattens, reduce exposure quickly because multiple compression can happen in days, not months.
• Monitor clinical and regulatory headlines around in vivo CAR-T as a longer-dated catalyst; if early data is credible, the market may start capitalizing the platform value within 6-12 months, supporting an additional rerating.